Stocklytics Platform
Asset logo for symbol RCKT
Rocket Pharmaceuticals
RCKT41
$11.68arrow_drop_up2.27%$0.25
Asset logo for symbol RCKT
RCKT41

$11.68

arrow_drop_up2.27%

Performance History

Chart placeholder
Key Stats
Open$11.50
Prev. Close$11.43
EPS-2.73
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range11.38
12.31
52 Week Range11.18
32.52
Ratios
Revenue-
EBITDA Margin %-
EPS-2.73

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Rocket Pharmaceuticals (RCKT)

Rocket Pharmaceuticals Inc (RCKT) is a biotechnology company focused on the development and commercialization of gene therapies for rare and devastating childhood diseases. The company's vision is to bring hope to patients and their families by advancing innovative treatments that address the underlying cause of these diseases. With a deep understanding of the genetic basis of these conditions, Rocket Pharmaceuticals is dedicated to revolutionizing the treatment landscape and improving patients' lives.
One key aspect of Rocket Pharmaceuticals' strategy is its gene therapy platform, which utilizes lentiviral vectors to deliver therapeutic genes to target cells. This approach has shown promising results in preclinical and clinical studies, demonstrating the potential to provide long-term, sustainable benefits for patients. By correcting or restoring the faulty genes responsible for these diseases, Rocket Pharmaceuticals aims to provide durable and curative treatments that can significantly impact patients' quality of life.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Gaurav D. Shah M.D.
Headquarters
Cranbury
Employees
240
Exchange
NASDAQ
add Rocket Pharmaceuticals  to watchlist

Keep an eye on Rocket Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Rocket Pharmaceuticals 's (RCKT) price per share?

The current price per share for Rocket Pharmaceuticals (RCKT) is $11.68. The stock has seen a price change of $0.26 recently, indicating a 2.27% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Rocket Pharmaceuticals (RCKT)?

For Rocket Pharmaceuticals (RCKT), the 52-week high is $32.52, which is 178.47% from the current price. The 52-week low is $11.18, the current price is 4.47% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Rocket Pharmaceuticals (RCKT) a growth stock?

Rocket Pharmaceuticals (RCKT) has shown an average price growth of -5.34% over the past three years. It has received a score of 40 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Rocket Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Rocket Pharmaceuticals (RCKT) stock price performance year to date (YTD)?

As of the latest data, Rocket Pharmaceuticals (RCKT) has a year-to-date price change of -60.41%. Over the past month, the stock has experienced a price change of -17.16%. Over the last three months, the change has been -40.95%. Over the past six months, the figure is -51.45%. Looking at a longer horizon, the five-year price change stands at -50.23%.
help

Is Rocket Pharmaceuticals (RCKT) a profitable company?

Rocket Pharmaceuticals (RCKT) has a net income of -$245.6M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$259.66M. Furthermore, the EBITDA is -$264.84M.
help

What is the market capitalization of Rocket Pharmaceuticals (RCKT)?

Rocket Pharmaceuticals (RCKT) has a market capitalization of $1.24B. The average daily trading volume is 11.7, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level